Faron is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. Its lead program is bexmarilimab, its investigative precision immunotherapy in Phase I/II development as a novel macrophage checkpoint immunotherapy for patients with hematological malignancies. Bexmarilimab is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation. Faron is based in Turku, Finland and Boston, Massachusetts. Faron is listed on AIM under the ticker ‘FARN’ and Nasdaq First North Growth Market ("Nasdaq First North") under ticker FARON.
Company Details
- Employees
- 54
- Founded
- -
- Address
- Joukahaisenkatu 6, Turku,20520,finland
- Phone
- 35802469515
- ma****@****als.com
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- faron.com
- Keywords
- Drug discovery, Drug development, Pharmaceuticals, Novel treatments for medical conditions with significant unmet needs, ARDS, Acute Respiratory Distress Syndrome, Cancer immunotherapy, biopharmaceutical.
- HQ
- Turku
Faron Questions
Faron's helpline number is 35802469515
Faron's website is faron.com
Faron's LinkedIn profile is https://fi.linkedin.com/company/faron
Faron has
54 employees.
View email and phone details for 54
employees at Faron.
Faron's industry is
Pharmaceutical Manufacturing
Faron's top competitors are
Valo Therapeutics Ltd,
Finvector Oy,
Roche Finland,
Nanoform,
Orion Pharma,
Medix Biochemica,
Medfiles,
Herantis Pharma Plc.,
Tilt Biotherapeutics Ltd,
Delsitech Ltd.
Faron's support email address is markku.jalkanen@faronpharmaceuticals.com
Faron's categories are Pharmaceutical Manufacturing
Faron's founding year is 2007
